Freely Filtered 054: EMPA Kidney!
Freely Filtered, a NephJC Podcast
00:00
The CKD Trials
I think these drugs clearly have cardiovascular benefits, particularly for hospitalization for heart failure. I think this is probably just a low risk population where it's more difficult to demonstrate a clear effect. One of the exclusion criteria is having type 2 diabetes and prior course atherosclerotic disease with an EGFR greater than 60. So there's no equipoise in the randomizing these patients. But when it comes to the UACR, the effect size for...
Transcript
Play full episode
